Microwave-Accelerated Coupling-Isomerization Reaction (MACIR) – A General Coupling-Isomerization Synthesis of 1,3-Diarylprop-2-en-1-ones
作者:Oana G. Schramm (née Dediu)、Thomas J. J. Müller
DOI:10.1002/adsc.200600280
日期:2006.12
The microwave-acceleratedcoupling-isomerizationreaction (MACIR) of (hetero)aryl halides and propargyl alcohols represents a general Pd/Cu and base-catalyzed process for the synthesis of 3-arylprop-2-en-1-ones in good yields.
IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF
申请人:Ahmed Kamal
公开号:US20130066081A1
公开(公告)日:2013-03-14
The present invention provides Chalcone linked Imidazolone compounds of formula A as anti cancer agent against fifty three human cancer cell lines.
wherein
本发明提供了一种化合物A的茚酮偶氮酮类抗癌剂,针对五十三种人类癌细胞系。
Heterobicyclic derivatives
申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
公开号:US20020107251A1
公开(公告)日:2002-08-08
Heterobicyclic derivatives of the formula:
1
wherein
R
1
is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s),
R
2
is aryl which may have suitable substituent(s) or heterocyclic group, and
R
3
is hydrogen, lower alkoxy or arylthio,
and a pharmaceutically acceptable salt thereof which are useful as a medicament.
Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors
申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
公开号:EP0920867A1
公开(公告)日:1999-06-09
Heterobicyclic derivatives of formula (I) wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as PDE IV and TNF inhibitors for the treatment of hepatitis in human beings and animals.